MAY-20-13 Dr. Ronald Valdiserri writes to recognize the second anniversary of Combating the
Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care
& Treatment of Viral Hepatitis and to share
an important announcement from Dr. Howard Koh about plans to update and renew the
existing plan through
MAY-16-13 Dr. Howard Koh, the Assistant Secretary for Health, announced on May 16 that the partner agencies are committed and dedicated to renewing the Action Plan for another three years and are currently working on their vision and priorities for 2014-2016.
Global Surveillance of Antiretroviral Drug Safety
Considerable progress has been made in providing global access to antiretroviral therapy. However, the effectiveness of treatment programs risks being compromised by problems related to toxicity, intolerance, drug-drug interactions, diversion, counterfeiting, inappropriate drug utilization and other issues. These are examples of common phenomena affecting individual patients and public health, but not identified before clinical use and scarcely systematically reported in countries with limited infrastructures for monitoring of drug use and safety.
This meeting was convened on June 11, 2010, in Washington, DC, with support from the Bill and Melinda Gates Foundation. Meeting participants included representatives from governments, global health organizations, industry, regulatory agencies, foundations, academia and implementers.
Multiple efforts are underway to improve antiretroviral drug (ARV) surveillance systems in low- and middle-income countries. All stakeholders must be engaged to ensure collaboration. The goal of this meeting is to convene these stakeholders to achieve synergy.
Nyasha Bakare, MD, MPH